Anakinra was the first drug targeting IL-1 to be approved as a therapeutic agent for rheumatoid arthritis, and has now been recognized as having excellent long-term safety for treatment of chronic diseases such as cryopyrin-associated periodic syndromes, which are related to pathogenic variants of IL-1s [19,20]. Here, IL1B is linked to rheumatoid arthritis.